Prime Medicine (PRME) Competitors $3.55 +0.33 (+10.25%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.57 +0.02 (+0.56%) As of 08/22/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. MESO, ADPT, ANIP, CGON, VCEL, SRPT, BEAM, ARQT, TWST, and SPRYShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Mesoblast (MESO), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), Vericel (VCEL), Sarepta Therapeutics (SRPT), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Twist Bioscience (TWST), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Mesoblast Adaptive Biotechnologies ANI Pharmaceuticals CG Oncology Vericel Sarepta Therapeutics Beam Therapeutics Arcutis Biotherapeutics Twist Bioscience ARS Pharmaceuticals Mesoblast (NASDAQ:MESO) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Is MESO or PRME more profitable? Mesoblast's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Prime Medicine N/A -107.87%-74.97% Do analysts recommend MESO or PRME? Mesoblast presently has a consensus price target of $18.00, indicating a potential upside of 13.85%. Prime Medicine has a consensus price target of $8.92, indicating a potential upside of 151.17%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has better valuation & earnings, MESO or PRME? Mesoblast has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M343.00-$87.96MN/AN/APrime Medicine$4.96M96.30-$198.13M-$1.56-2.28 Do insiders and institutionals believe in MESO or PRME? 1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, MESO or PRME? Mesoblast has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Does the media prefer MESO or PRME? In the previous week, Prime Medicine had 1 more articles in the media than Mesoblast. MarketBeat recorded 3 mentions for Prime Medicine and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.76 beat Prime Medicine's score of 0.37 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMesoblast beats Prime Medicine on 9 of the 14 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$477.74M$284.09M$5.82B$21.32BDividend YieldN/AN/A4.40%3.52%P/E Ratio-1.73N/A31.3029.16Price / Sales96.30563.89455.2955.66Price / CashN/A22.4438.0224.09Price / Book2.5910.439.535.47Net Income-$198.13M-$115.81M$3.26B$992.74M7 Day Performance-0.56%-0.75%2.13%2.67%1 Month Performance-18.39%-4.91%3.21%2.35%1 Year Performance-19.68%-8.26%30.18%10.76% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine2.7332 of 5 stars$3.55+10.2%$8.92+151.2%-19.7%$477.74M$4.96M-1.73234Gap UpMESOMesoblast2.0771 of 5 stars$14.70-2.2%$18.00+22.4%+141.0%$1.88B$5.90M0.0080News CoverageUpcoming EarningsADPTAdaptive Biotechnologies2.4124 of 5 stars$12.15-0.4%$12.38+1.9%+167.5%$1.85B$178.96M-14.82790News CoverageAnalyst RevisionANIPANI Pharmaceuticals3.1667 of 5 stars$84.88+4.2%$84.75-0.2%+47.6%$1.84B$674.07M-110.23600News CoverageAnalyst UpgradeInsider TradeHigh Trading VolumeCGONCG Oncology1.3789 of 5 stars$23.94-3.7%$55.30+131.0%-27.3%$1.82B$1.14M-13.5361VCELVericel2.4911 of 5 stars$35.43-2.2%$60.33+70.3%-24.9%$1.79B$249.12M295.27300Positive NewsSRPTSarepta Therapeutics4.5656 of 5 stars$17.94-1.6%$44.17+146.2%-85.6%$1.75B$2.48B-20.621,372Trending NewsAnalyst ForecastShort Interest ↑BEAMBeam Therapeutics2.2363 of 5 stars$17.17-2.6%$48.45+182.2%-37.9%$1.74B$63.52M-3.82510ARQTArcutis Biotherapeutics1.8009 of 5 stars$14.19-3.9%$19.80+39.5%+62.6%$1.70B$196.54M-18.92150News CoveragePositive NewsTWSTTwist Bioscience4.1612 of 5 stars$27.63+7.8%$49.40+78.8%-34.5%$1.67B$312.97M-19.06990Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals2.4651 of 5 stars$16.38-6.4%$31.00+89.3%+4.2%$1.61B$97.12M-102.3790Insider Trade Related Companies and Tools Related Companies Mesoblast Alternatives Adaptive Biotechnologies Alternatives ANI Pharmaceuticals Alternatives CG Oncology Alternatives Vericel Alternatives Sarepta Therapeutics Alternatives Beam Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Twist Bioscience Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredThe New Way Retirees Are Getting Paid Extra Every MonthBloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access